Not Yet RecruitingNot Applicable

The Effect of Catheter Protector on Catheter Dwell Time and Complications

70 participantsStarted 2024-11-01

Plain-language summary

Objective: This study aimed to determine the effect of applying the IV House Ultradressing catheter protector on the frequency of peripheral venous catheter (PVC) replacements and complications in patients with peripheral venous catheterization in an oncology clinic. Materials and Methods: The research was planned as a randomized controlled experimental study. The population of the study consisted of patients hospitalized in the oncology clinic. The sample of the study was calculated based on the data from the study by Büyükyılmaz et al. (2019), which found a significant difference in the average duration of catheter-related phlebitis in the intervention group (2.10 ± 1.55 days) compared to the control group (1.27 ± 0.45 days), with an effect size of d=0.72. As a result of the sample size calculation, 32 patients were predicted for each group. Considering that 10% of patients might drop out during the study, a total of 70 patients, with 35 in each group, were decided to be included. After the catheter is inserted, patients in the intervention group will have their catheter area protected with IV House Ultradressing, while no protective measures will be applied to the control group. Both groups will be evaluated in terms of catheter duration and PVC complications. It is planned to use t-tests and chi-square tests for data analysis.

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Inclusion Criteria * Hospitalized in the oncology clinic * The one with the PVK attached, * Volunteered to participate in the research, * Treated in the same clinic during the study period, * No verbal, perceptual and visual communication problems, * 22-24 G (Blue) size catheter used, * Between the ages of 18 and 65, * Literate, * Patients without scar tissue, infection, hematoma, edema at the sites to be used for PVK placement were included in the study. Exclusion Criteria: * \- With a clotting disorder, * Patients with problems with skin integrity or limb movement such as scar tissue, infection, hematoma, edema at the PVK site, * Blood or blood products given through a catheter, * Patients who wanted to leave, were referred to a different clinic or discharged during the study were excluded from the study.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Phlebitis Follow up Form

Timeframe: up to 1 weeks

PIVC Length of Stay Follow up Form

Timeframe: up to 1 weeks

Infiltration Follow up Form

Timeframe: up to 1 weeks

Extravasation Follow up Form

Timeframe: up to 1 weeks

Occlusion Follow up Form

Timeframe: up to 1 weeks

Folding Follow up Form

Timeframe: up to 1 weeks

Dislocation Follow up Form

Timeframe: up to 1 weeks

Trial details

NCT IDNCT06675786

SponsorKaramanoğlu Mehmetbey University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-05-30

Contact for this trial

Tuğba DOST, Öğr. Gör. Dr.

+905065031187 t.demiroglu1@gmail.com

View on ClinicalTrials.gov More Peripheral Catheterization trials

Plain-language summary

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.